CHEK Stock Overview
A clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Check-Cap Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.19 |
| 52 Week High | US$3.45 |
| 52 Week Low | US$0.56 |
| Beta | 0.10 |
| 1 Month Change | 47.28% |
| 3 Month Change | 1.33% |
| 1 Year Change | -45.41% |
| 3 Year Change | -91.38% |
| 5 Year Change | -96.56% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Jul 19
Here's Why We're Watching Check-Cap's (NASDAQ:CHEK) Cash Burn Situation
Feb 05We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Sep 03Here's Why We're Not Too Worried About Check-Cap's (NASDAQ:CHEK) Cash Burn Situation
May 19We Think Check-Cap (NASDAQ:CHEK) Can Afford To Drive Business Growth
Feb 03We're Hopeful That Check-Cap (NASDAQ:CHEK) Will Use Its Cash Wisely
Oct 21Check-Cap (NASDAQ:CHEK) Is In A Good Position To Deliver On Growth Plans
Jul 01We're Keeping An Eye On Check-Cap's (NASDAQ:CHEK) Cash Burn Rate
Jan 02
Check Cap +1.5% on listing extension from NASDAQ
Dec 30Check-Cap EPS misses by $0.01
Nov 18Shareholder Returns
| CHEK | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 108.6% | 2.7% | 2.8% |
| 1Y | -45.4% | 10.6% | 24.6% |
Return vs Industry: CHEK underperformed the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: CHEK underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| CHEK volatility | |
|---|---|
| CHEK Average Weekly Movement | 81.2% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CHEK's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CHEK's weekly volatility has increased from 41% to 81% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 85 | n/a | www.check-cap.com |
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
Check-Cap Ltd. Fundamentals Summary
| CHEK fundamental statistics | |
|---|---|
| Market cap | US$9.07m |
| Earnings (TTM) | -US$17.57m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs CHEK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHEK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.57m |
| Earnings | -US$17.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CHEK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 10:35 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Check-Cap Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Kyle Bauser | Colliers Securities |
| Yi Chen | H.C. Wainwright & Co. |